by nms-sync | Sep 29, 2021 | News
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue.
The annual list showcases companies that are providing cutting-edge drug...
by nms-sync | Sep 14, 2021 | News
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency...
by nms-sync | Jun 30, 2021 | News
Nerviano, 30 June 2021
Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process.
The...
by nms-sync | Feb 9, 2021 | News
Nerviano, 9 February 2021
NMS Group has been named the winner of the “Value creators’ category at the prestigious ‘China Awards 2021′ during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value...
Welcome and Check out our new motion picture!
Recent Comments